Clinical Trial Update: A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the adverse events, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, leucovorin, and budigalimab in ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• ABBV-400
• FLUOROURACIL (Fluorouracil)
• Leucovorin (folinic acid)
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING